Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake.

Cheng Q, Wållberg H, Grafström J, Lu L, Thorell JO, Hägg Olofsson M, Linder S, Johansson K, Tegnebratt T, Arnér ES, Stone-Elander S, Ahlzén HS, Ståhl S; Sel-tag imaging project.

EJNMMI Res. 2016 Dec;6(1):58. doi: 10.1186/s13550-016-0213-8. Epub 2016 Jul 7.

2.

Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.

Cilliers C, Guo H, Liao J, Christodolu N, Thurber GM.

AAPS J. 2016 Sep;18(5):1117-30. doi: 10.1208/s12248-016-9940-z. Epub 2016 Jun 10.

PMID:
27287046
3.

Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET.

Kim JS.

Nucl Med Mol Imaging. 2016 Jun;50(2):104-11. doi: 10.1007/s13139-015-0392-7. Epub 2016 Jan 26. Review.

4.

Targeted erythropoietin selectively stimulates red blood cell expansion in vivo.

Burrill DR, Vernet A, Collins JJ, Silver PA, Way JC.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):5245-50. doi: 10.1073/pnas.1525388113. Epub 2016 Apr 25.

PMID:
27114509
5.

Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer.

Winner KR, Steinkamp MP, Lee RJ, Swat M, Muller CY, Moses ME, Jiang Y, Wilson BS.

Cancer Res. 2016 Mar 15;76(6):1320-34. doi: 10.1158/0008-5472.CAN-15-1620. Epub 2015 Dec 30.

PMID:
26719526
6.

Molecular Imaging of Pancreatic Cancer with Antibodies.

England CG, Hernandez R, Eddine SB, Cai W.

Mol Pharm. 2016 Jan 4;13(1):8-24. doi: 10.1021/acs.molpharmaceut.5b00626. Epub 2015 Dec 10.

7.

Mathematical framework for activity-based cancer biomarkers.

Kwong GA, Dudani JS, Carrodeguas E, Mazumdar EV, Zekavat SM, Bhatia SN.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12627-32. doi: 10.1073/pnas.1506925112. Epub 2015 Sep 28.

8.

A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering.

Kruziki MA, Bhatnagar S, Woldring DR, Duong VT, Hackel BJ.

Chem Biol. 2015 Jul 23;22(7):946-56. doi: 10.1016/j.chembiol.2015.06.012. Epub 2015 Jul 9.

9.

HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats.

Marroquin Belaunzaran O, Kleber S, Schauer S, Hausmann M, Nicholls F, Van den Broek M, Payeli S, Ciurea A, Milling S, Stenner F, Shaw J, Kollnberger S, Bowness P, Petrausch U, Renner C.

PLoS One. 2015 Jun 30;10(6):e0130811. doi: 10.1371/journal.pone.0130811. eCollection 2015.

10.

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.

Maruani A, Smith ME, Miranda E, Chester KA, Chudasama V, Caddick S.

Nat Commun. 2015 Mar 31;6:6645. doi: 10.1038/ncomms7645.

11.

Antibody Drug Conjugates: Preclinical Considerations.

Bornstein GG.

AAPS J. 2015 May;17(3):525-34. doi: 10.1208/s12248-015-9738-4. Epub 2015 Feb 28. Review.

12.

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Sockolosky JT, Szoka FC.

Adv Drug Deliv Rev. 2015 Aug 30;91:109-24. doi: 10.1016/j.addr.2015.02.005. Epub 2015 Feb 19. Review.

13.

The Impact of Aspect Ratio on the Biodistribution and Tumor Homing of Rigid Soft-Matter Nanorods.

Shukla S, Eber FJ, Nagarajan AS, DiFranco NA, Schmidt N, Wen AM, Eiben S, Twyman RM, Wege C, Steinmetz NF.

Adv Healthc Mater. 2015 Apr 22;4(6):874-82. doi: 10.1002/adhm.201400641. Epub 2015 Jan 13.

14.

The history of monoclonal antibody development - Progress, remaining challenges and future innovations.

Liu JK.

Ann Med Surg (Lond). 2014 Sep 11;3(4):113-6. doi: 10.1016/j.amsu.2014.09.001. eCollection 2014 Dec. Review.

15.

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model.

Pak Y, Pastan I, Kreitman RJ, Lee B.

PLoS One. 2014 Oct 24;9(10):e110716. doi: 10.1371/journal.pone.0110716. eCollection 2014.

16.

Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.

Jackson D, Stover D.

Pharm Res. 2015 Nov;32(11):3458-69. doi: 10.1007/s11095-014-1536-7. Epub 2014 Oct 23. Review.

17.

The development of immunoconjugates for targeted cancer therapy.

Smaglo BG, Aldeghaither D, Weiner LM.

Nat Rev Clin Oncol. 2014 Nov;11(11):637-48. doi: 10.1038/nrclinonc.2014.159. Epub 2014 Sep 30. Review.

18.

Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals.

Vainshtein I, Roskos LK, Cheng J, Sleeman MA, Wang B, Liang M.

Pharm Res. 2015 Jan;32(1):286-99. doi: 10.1007/s11095-014-1462-8. Epub 2014 Sep 11.

19.

T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell.

Roskopf CC, Schiller CB, Braciak TA, Kobold S, Schubert IA, Fey GH, Hopfner KP, Oduncu FS.

Oncotarget. 2014 Aug 15;5(15):6466-83.

20.

Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Cao Y, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2014 Aug;41(4):375-87. doi: 10.1007/s10928-014-9372-2. Epub 2014 Jul 31.

Items per page

Supplemental Content

Write to the Help Desk